| LLY |
Eli Lilly and Company |
95%
|
ervice institutions, non-profit clinics, and Federal government entities purchasing via the Federal Supply Schedule, purchase directly from our wholesalers. Contracted customers generally purchase th… |
| LLY |
Eli Lilly and Company |
95%
|
Reciprocal relationship from LLY graph: Reciprocal relationship from INCY graph: Reciprocal relationship from LLY graph: Reciprocal relationship from INCY graph: Reciprocal relationship from LLY grap… |
| MGNX |
MacroGenics, Inc. |
90%
|
Reciprocal relationship from MGNX graph: the Company’s Global Collaboration and License Agreement dated as of October 24, 2017, as amended (the “License Agreement”), with Incyte Corporation |
| NVSEF |
Novartis AG |
72%
|
(in thousands): December 31, 2024 2023 Raw materials $ 27,590 $ 23,282 API and Work-in-process 331,178 209,793 Finished goods 48,431 36,862 Total inventory $ 407,199 $ 269,937 Inventories, stated at … |
| NVSEF |
Novartis AG |
72%
|
Reciprocal relationship from NVSEF graph: Reciprocal relationship from INCY graph: (in thousands): December 31, 2024 2023 Raw materials $ 27,590 $ 23,282 API and Work-in-process 331,178 209,793 Finis… |
| ORANY |
ORANY |
72%
|
pabilities may be disproportional compared to the revenues we may be able to generate on sales of our products. We are continuing to establish and maintain sales, marketing and distribution capabilit… |
| ORANY |
ORANY |
72%
|
Reciprocal relationship from ORANY graph: Reciprocal relationship from INCY graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from INCY graph: Reciprocal relationship from ORAN… |
| PRLD |
Prelude Therapeutics Incorporated |
72%
|
sive of amendments to the agreement, through March 31, 2026, we have paid MacroGenics developmental and regulatory milestones totaling $ 215.0 million. After these amendments and subsequent payments,… |
| PRLD |
Prelude Therapeutics Incorporated |
72%
|
Reciprocal relationship from PRLD graph: Reciprocal relationship from INCY graph: Reciprocal relationship from PRLD graph: Reciprocal relationship from INCY graph: Reciprocal relationship from PRLD g… |
| SNDX |
Syndax Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from SNDX graph: Reciprocal relationship from INCY graph: ent of operations. Research and development expenses for the period from January 1, 2024 to the asset acquisition on … |
| SNDX |
Syndax Pharmaceuticals, Inc. |
72%
|
ent of operations. Research and development expenses for the period from January 1, 2024 to the asset acquisition on February 5, 2024, includes $ 10.7 million, related to our 55 % share of the co-dev… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
Reciprocal relationship from TKPHF graph: Reciprocal relationship from INCY graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from INCY graph: esting. Compensation expense for … |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
esting. Compensation expense for PSUs with market performance conditions is calculated using a Monte Carlo simulation model as of the date of grant and recorded over the requisite service period. Adv… |
| AGENUS-SWITZERLAND-INC |
AGENUS-SWITZERLAND-INC |
62%
|
(in thousands): December 31, 2024 2023 Raw materials $ 27,590 $ 23,282 API and Work-in-process 331,178 209,793 Finished goods 48,431 36,862 Total inventory $ 407,199 $ 269,937 Inventories, stated at … |
| ALKEM-LABORATORIES-LTD |
ALKEM-LABORATORIES-LTD |
62%
|
e revenues we may be able to generate on sales of our products. We are continuing to establish and maintain sales, marketing and distribution capabilities for our products. Successful commercializati… |
| ANTIBODY-AG |
ANTIBODY-AG |
62%
|
(in thousands): December 31, 2024 2023 Raw materials $ 27,590 $ 23,282 API and Work-in-process 331,178 209,793 Finished goods 48,431 36,862 Total inventory $ 407,199 $ 269,937 Inventories, stated at … |
| APOTEX-INC-HIKMA-PHARMACEUTICALS-USA-INC-SUN-PHA |
APOTEX-INC-HIKMA-PHARMACEUTICALS-USA-INC-SUN-PHA |
62%
|
e revenues we may be able to generate on sales of our products. We are continuing to establish and maintain sales, marketing and distribution capabilities for our products. Successful commercializati… |
| ARIAD-PHARMACEUTICALS-INC |
ARIAD-PHARMACEUTICALS-INC |
62%
|
esting. Compensation expense for PSUs with market performance conditions is calculated using a Monte Carlo simulation model as of the date of grant and recorded over the requisite service period. Adv… |
| CALITHERA-BIOSCIENCES-INC |
CALITHERA-BIOSCIENCES-INC |
62%
|
may receive if these drug candidates receive regulatory approval and are commercialized in the relevant territories will depend primarily on the development and commercialization efforts of others. W… |
| CHIEF-HUMAN-RESOURCES |
CHIEF-HUMAN-RESOURCES |
62%
|
applicable regulatory requirements, we could incur significant delays in our clinical trials or interruption of commercial supply which could have a material adverse effect on our business. We have e… |
| CHINA-MEDICAL-SYSTEM-HOLDINGS-LIMITED |
CHINA-MEDICAL-SYSTEM-HOLDINGS-LIMITED |
62%
|
ent of operations. Research and development expenses for the period from January 1, 2024 to the asset acquisition on February 5, 2024, includes $ 10.7 million, related to our 55 % share of the co-dev… |
| CHINA-MEDICAL-SYSTEMS-HOLDINGS-LIMITED |
CHINA-MEDICAL-SYSTEMS-HOLDINGS-LIMITED |
62%
|
ent of operations. Research and development expenses for the period from January 1, 2024 to the asset acquisition on February 5, 2024, includes $ 10.7 million, related to our 55 % share of the co-dev… |
| ESCIENT-PHARMACEUTICALS-INC |
ESCIENT-PHARMACEUTICALS-INC |
62%
|
ange in the accruals from prior periods, and assessed the historical accuracy of management’s estimates against actual results. We also tested the completeness and accuracy of the underlying data use… |
| ESCIENT-PHARMACEUTICS-INC |
ESCIENT-PHARMACEUTICS-INC |
62%
|
ange in the accruals from prior periods, and assessed the historical accuracy of management’s estimates against actual results. We also tested the completeness and accuracy of the underlying data use… |
| GRANULES-INDIA-LTD |
GRANULES-INDIA-LTD |
62%
|
e revenues we may be able to generate on sales of our products. We are continuing to establish and maintain sales, marketing and distribution capabilities for our products. Successful commercializati… |
| HIKMA-PHARMACEUTICALS-USA-INC |
HIKMA-PHARMACEUTICALS-USA-INC |
62%
|
e revenues we may be able to generate on sales of our products. We are continuing to establish and maintain sales, marketing and distribution capabilities for our products. Successful commercializati… |
| INC-GRANULES-INDIA-LTD |
INC-GRANULES-INDIA-LTD |
62%
|
e revenues we may be able to generate on sales of our products. We are continuing to establish and maintain sales, marketing and distribution capabilities for our products. Successful commercializati… |
| INNOVENT-BIOLOGICS-INC |
INNOVENT-BIOLOGICS-INC |
62%
|
ervice institutions, non-profit clinics, and Federal government entities purchasing via the Federal Supply Schedule, purchase directly from our wholesalers. Contracted customers generally purchase th… |
| LABORATORIES-INC-EUGIA-PHARMA-SPECIALTIES-LTD |
LABORATORIES-INC-EUGIA-PHARMA-SPECIALTIES-LTD |
62%
|
e revenues we may be able to generate on sales of our products. We are continuing to establish and maintain sales, marketing and distribution capabilities for our products. Successful commercializati… |
| MORPHOSYS-AG |
MORPHOSYS-AG |
62%
|
(in thousands): December 31, 2024 2023 Raw materials $ 27,590 $ 23,282 API and Work-in-process 331,178 209,793 Finished goods 48,431 36,862 Total inventory $ 407,199 $ 269,937 Inventories, stated at … |
